liam

💉The 2026 Anaphylaxis Guidelines highlight something uncomfortable for all of us in acute care: we do not fail because we lack knowledge, but because we fail to act on what we already know. Across 12 international guidelines, there is almost perfect agreement on one point: intramuscular epinephrine is the first and most important intervention⚠️. Yet in real practice, it remains significantly underused, often replaced or delayed by antihistamines or corticosteroids, therapies with no evidence for acute life saving benefit This gap between evidence and behavior is the central clinical problem. From a bedside perspective, three insights are particularly relevant: First, diagnosis remains the main bottleneck, not treatment. The guidelines clearly show that variability in diagnostic criteria, especially in patients without skin manifestations or in infants, leads to hesitation. Clinically, this reinforces a key principle: -> anaphylaxis is a clinical diagnosis driven by physiology, not by complete textbook criteria. Waiting for skin signs or full multisystem involvement delays epinephrine and worsens outcomes. Second, the document reframes management from a pharmacologic problem to a systems and education problem. Underrecognition by clinicians, lack of training in schools and community settings, and poor patient education all contribute to undertreatment. In reality, the success of anaphylaxis management depends less on ICU level interventions and more on early recognition and immediate action in prehospital environments. Third, there is a clear shift toward proactive risk management rather than reactive treatment. Modern guidelines emphasize emergency action plans, patient carried epinephrine, and structured education programs. This aligns with a broader trend in critical care: outcomes improve when interventions occur before physiological collapse, not after. An important nuance for critical care physicians is the role of adjunctive therapies. Antihistamines and corticosteroids are consistently positioned as SECONDARY, non life saving treatments. Their continued overuse reflects a cognitive bias toward treating visible symptoms rather than addressing the underlying hemodynamic and airway threat. Clinically, this is equivalent to treating hypotension in septic shock with paracetamol. 🤓Bottom line: Anaphylaxis is one of the clearest examples in medicine where the evidence is simple, but implementation fails. The priority is not new drugs or devices, but closing the gap between recognition and immediate epinephrine administration. 📃Reference Wallace DV, Immunol Allergy Clin N Am ▪ (2026) doi.org/10.1016/j.iac.2026.0…